Search clinical trials for: Investigational HIV vaccine dose A

Total 2422 results

Institut Pasteur

Completed

Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine

HIV

Belgium
Sinovac Biotech Co., Ltd

Completed

Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)

Hepatitis B

China
GlaxoSmithKline
Biological E. Limited

Recruiting

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Typhoid Fever

Belgium
GlaxoSmithKline

Active, not recruiting

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

Sexually Transmitted Diseases

United States, Germany, Philippines, France, Spain, South Africa, United Kingdom, Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Respiratory Syncytial Virus (RSV)

United States
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Covid19

United States
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Influenza, Human

United States
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
GlaxoSmithKline
Kwame Nkrumah University of Science and Technology; European & Developing Countries... and other collaborators

Recruiting

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Salmonella Infections

Ghana
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

Infections, Staphylococcal

Belgium
Laval University

Completed

Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.

Human Papillomavirus

Canada
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
GlaxoSmithKline
IQVIA, USA

Active, not recruiting

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox

Taiwan, Poland, United States, Estonia, Puerto Rico, Mexico
The University of Texas Medical Branch, Galveston
Cancer Prevention Research Institute of Texas

Active, not recruiting

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

Efficacy | Human Papilloma Virus | Immunization

United States
Jiangsu Province Centers for Disease Control and...
Royal (Wuxi) Biological Co., LTD

Completed

Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children

Group A, C Polysaccharide Meningitis | Type b Haemophilus Influenza

China
Sinovac Biotech Co., Ltd

Completed

Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults

Hepatitis A

China
Jiangsu Province Centers for Disease Control and...
Royal (Wuxi) Biological Co., LTD

Completed

Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine

Influenza | Meningitis

China
Institute of Medical Biology, Chinese Academy of...
Jiangsu Province Centers for Disease Control and Prevention

Completed

The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines (HAV)

Hepatitis A

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Prevention of Influenza

China
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)

Cervical Cancer | HPV | Premalignancy Anogenital Warts
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Germany
Federal Budgetary Research Institution State Research...

Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
HK inno.N Corporation

Unknown

Safety and Immunogenicity of CJ-40010 in Healthy Subjects

Hand, Foot and Mouth Disease

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Withdrawn

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Influenza
Tor Biering-Sørensen
Sanofi; Statens Serum Institut

Recruiting

A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults (DANFLU-2)

Influenza

Denmark
Tor Biering-Sørensen
Sanofi Pasteur, a Sanofi Company

Completed

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting (DANFLU-1)

Influenza

Denmark
Ningbo Rongan Biological Pharmaceutical Co., Ltd.

Not yet recruiting

Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)

Rabies

China
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Malaria

Malawi
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Influenza

Japan
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Jiangsu Province Center for...

Active, not recruiting

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Varicella

China
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

Panama, New Zealand, South Africa
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
University of Wisconsin, Madison

Completed

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

Inflammatory Bowel Disease (IBD)

United States
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company; Bioster, a.s.

Completed

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 (COVIMMUNAGE)

Covid19

France
GlaxoSmithKline

Completed

Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years

Influenza

Slovakia, Estonia
GlaxoSmithKline

Completed

Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Thailand

3

Subscribe